Given the current scenario, anti-TNFR2 immunotherapy, either alone or in conjunction with anti-PD-1, significantly changed the TEM to eliminate tumor-specific Tregs and enhance Teff cells [44]. The gene discussed is PDCD1; the disease is neoplasm.